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The dose of protamine required following cardiopulmonary bypass (CPB) is often deter-
mined by the dose of heparin required pre-CPB, expressed as a fixed ratio. Dosing based
on mathematical models of heparin clearance is postulated to improve protamine dosing
precision and coagulation. We hypothesised that protamine dosing based on a 2-compart-
ment model would improve thromboelastography (TEG) parameters and reduce the dose of
protamine administered, relative to a fixed ratio.
Methods and findings
We undertook a 2-stage, adaptive randomised controlled trial, allocating 228 participants to
receive protamine dosed according to a mathematical model of heparin clearance or a fixed
ratio of 1 mg of protamine for every 100 IU of heparin required to establish anticoagulation
pre-CPB. A planned, blinded interim analysis was undertaken after the recruitment of 50%
of the study cohort. Following this, the randomisation ratio was adapted from 1:1 to 1:1.33 to
increase recruitment to the superior arm while maintaining study power. At the conclusion of
trial recruitment, we had randomised 121 patients to the intervention arm and 107 patients
to the control arm. The primary endpoint was kaolin TEG r-time measured 3 minutes after
protamine administration at the end of CPB. Secondary endpoints included ratio of kaolin
TEG r-time pre-CPB to the same metric following protamine administration, requirement for
allogeneic red cell transfusion, intercostal catheter drainage at 4 hours postoperatively, and
the requirement for reoperation due to bleeding. The trial was listed on a clinical trial registry
(ClinicalTrials.gov Identifier: NCT03532594).
Participants were recruited between April 2018 and August 2019. Those in the interven-
tion/model group had a shorter mean kaolin r-time (6.58 [SD 2.50] vs. 8.08 [SD 3.98] min-
utes; p = 0.0016) post-CPB. The post-protamine thromboelastogram of the model group
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was closer to pre-CPB parameters (median pre-CPB to post-protamine kaolin r-time ratio
0.96 [IQR 0.78–1.14] vs. 0.75 [IQR 0.57–0.99]; p < 0.001). We found no evidence of a differ-
ence in median mediastinal/pleural drainage at 4 hours postoperatively (140 [IQR 75–245]
vs. 135 [IQR 94–222] mL; p = 0.85) or requirement (as a binary outcome) for packed red
blood cell transfusion at 24 hours postoperatively (19 [15.8%] vs. 14 [13.1%] p = 0.69).
Those in the model group had a lower median protamine dose (180 [IQR 160–210] vs. 280
[IQR 250–300] mg; p < 0.001).
Important limitations of this study include an unblinded design and lack of generalisability
to certain populations deliberately excluded from the study (specifically children, patients
with a total body weight >120 kg, and patients requiring therapeutic hypothermia to <28˚C).
Conclusions
Using a mathematical model to guide protamine dosing in patients following CPB improved
TEG r-time and reduced the dose administered relative to a fixed ratio. No differences were
detected in postoperative mediastinal/pleural drainage or red blood cell transfusion require-
ment in our cohort of low-risk patients.
Trial registration
ClinicalTrials.gov Unique identifier NCT03532594.
Author summary
Why was this study done?
• Mathematical models of heparin clearance have been postulated to reduce protamine
dosing after cardiopulmonary bypass (CPB) and may improve clotting after cardiac
surgery.
• Best practice guidelines have been unable to provide firm recommendations for the use
of these models due to a lack of randomised clinical trial data.
• The PRODOSE trial was designed to address this gap in the evidence.
What did the researchers do and find?
• We tested a mathematical model designed to calculate a bespoke protamine dose in
patients undergoing cardiac surgery with CPB who were at a relatively low risk of bleed-
ing, comparing it to a fixed dose ratio that is currently used widely (1 mg of protamine
for every 100 IU of heparin given to establish safe anticoagulation before CPB, com-
monly known as a 1:1 fixed dose ratio).
• We found that using this mathematical model improved point-of-care measures of
coagulation and reduced the amount of protamine given by 36.6% relative to the 1:1
fixed dose ratio.
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• We did not find a difference in postoperative bleeding or use of blood products between
the groups. However, as this is a Phase II trial, the study was not designed to accurately
assess clinical outcomes, with an emphasis instead on safety and biochemical efficacy.
What do these findings mean?
• Our findings suggest that mathematical models of heparin clearance can be safely used
to dose protamine in the population studied and that dosing protamine according to the
commonly used 1:1 fixed dose ratio is probably excessive in this population.
• Clinicians could consider using PRODOSE or similar models in patients at lower risk of
bleeding after cardiac surgery in place of a 1:1 fixed dose ratio.
• Further research with a focus on clinical outcomes and a population at a higher risk of
bleeding is warranted.
Introduction
Adequate anticoagulation for cardiopulmonary bypass (CPB) is generally achieved using high
doses of unfractionated heparin and is reversed using protamine sulphate [1]. Protamine can
exert paradoxical anticoagulant (particularly inhibiting factor V activation and thrombin) and
antiplatelet effects when administered in excess to circulating heparin [2]. Higher doses of
protamine have been shown to increase the risk of transfusion and postoperative bleeding fol-
lowing cardiac surgery [3,4]. It is therefore prudent to dose protamine in such a way as to min-
imise these effects, while also ensuring effective heparin reversal.
Approaches to protamine dosing vary widely [5,6]. A common recommendation is a fixed
1:1 (1-mg protamine to every 100 IU of heparin) ratio based on the initial dose of heparin
required to establish therapeutic anticoagulation [1,7]. This method does not directly account
for heparin clearance and may lead to excessive protamine dosage [8]. Mathematical models
have been proposed to enable the clinician to estimate the amount of circulating heparin at
any time point based on common preoperative covariates, and thereby guide protamine
administration. While small, nonrandomised studies of different models have shown that
these approaches may improve coagulation and reduce protamine dose, uptake has been lim-
ited by a lack of prospective, randomised data [9]. To date, only 1 appropriately powered ran-
domised trial has been published [10], and best practice guidelines continue to recommend
the use of fixed dose ratios [11].
Following a pilot study [12], and having studied similar work [4,13], we hypothesised that
protamine dosing guided by a 2-compartment pharmacokinetic derivation of heparin clear-
ance would, relative to a conventional, fixed 1:1 ratio: (a) result in superior viscoelastic metrics
of coagulation in the post-CPB period in patients undergoing cardiac surgery; and (b) use less
protamine to achieve satisfactory haemostasis.
Methods
Trial design
We performed a 2-stage, adaptive randomised superiority trial. Patients in the first stage of the
trial were randomised with equal probability using a blocked randomisation procedure to the
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intervention (PRODOSE model) or control (fixed 1:1 ratio) arms. An interim analysis was
scheduled to check for safety, consider a predefined futility rule, and an adaptation of the ran-
domisation ratio based on the primary outcome data at that point aimed at maximising the
number of patients in the superior arm while maintaining study power. The trial was per-
formed at 2 centres—a dedicated cardiothoracic hospital in the United Kingdom and a ter-
tiary, university-affiliated hospital in Australia. Ethical approval was received from the UK
Health Research Authority (17/EE/0460) and the Austin Health Human Research Ethics
Committee (HREC/17/Austin/566). The trial was registered (ClinicalTrials.gov Identifier:
NCT03532594). All participants gave written informed consent prior to any study-related
procedures.
Study population
All patients presenting for cardiac surgery requiring CPB were considered for inclusion. War-
farin or novel oral anticoagulant therapy was ceased 5 or 3 days, respectively, prior to opera-
tion. Patients were excluded if they were<18 years old, had a total body weight >120 kg (due
to unpredictable heparin requirements in obese individuals) [14], were dialysis dependent,
had a known blood dyscrasia or platelet dysfunction, had received adenosine diphosphate
receptor antagonists within 7 days of surgery, had received an unfractionated heparin infusion
or therapeutic low molecular weight heparin <24 hours before surgery, required emergency
surgery (defined as operation before the beginning of the next working day after the decision
to operate was made), had an operative plan requiring therapeutic hypothermia to<28˚C, had
complex surgical requirements (redo sternotomy, surgery on aortic arch, or descending tho-
racic aorta), or were undergoing solid organ transplantation.
Coagulation management and conduct of cardiopulmonary bypass
A 2-g dose of tranexamic acid was administered to all patients prior to or with heparin. The
initial dose of heparin (heparin sodium, Fannin (UK), Measham, UK or Pfizer Australia, Syd-
ney, Australia) was 300 IU/kg based on total body weight, with a target activated clotting time
(ACT) of�400 seconds. Another 5,000 IU of heparin was added to the pump prime. CPB was
undertaken using flow rates of 2.2 to 2.5 min/m2. Nasopharyngeal temperature was managed
according to surgical preference (within the limitations of the protocol). The ACT was
repeated every 30 minutes, and additional heparin was administered if this was�400 seconds.
The administration of blood products in the operating room and for the first 24 hours postop-
eratively was based on standard institutional practices, codified to promote consistency (S1
Appendix).
Randomisation and intervention
Participants were randomised immediately prior to or following induction of anaesthesia. The
anaesthetist and surgeon were not blinded. Randomisation was implemented using a web-
based portal (Sealed Envelope, London, UK) and a random permuted block algorithm with a
block of size 4, stratified by centre to target the randomisation ratio established for each of the
trial stages. In the first stage of the trial, participants were randomised in a 1:1 ratio. At the
interim analysis, the randomisation ratio was adapted using primary outcome data up to that
point, following our design based on methods first described by Zhang and Rosenberger and
extended by simulations to accommodate violation of design assumptions (S2 Appendix) [15].
These predetermined rules aimed to maximise the number of patients in the treatment arm
trending towards statistical superiority, ensuring that most patients received better treatment
while preserving study power.
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The control group received protamine post-CPB at a fixed dose ratio of 1 mg for every 100
IU of unfractionated heparin administered in the pre-CPB period to obtain the target ACT.
This ratio was chosen as it is supported by expert guidance [11]. The intervention group
received protamine dosed according to the amount of residual heparin calculated to remain at
the end of CPB according to the PRODOSE model. Further doses of protamine were permitted
in the operating theatre or within 4 hours of arrival in the intensive care unit (ICU) following
the initial dose if thromboelastography (TEG) suggested residual heparinisation was present
or to correct for residual heparin in unprocessed pump blood administered to the participant.
Routine cell salvage was not employed at either institution for the management of the recruited
patient population.
The PRODOSE model
We previously performed a pilot study to validate a single-compartment pharmacokinetic
model that predicted elimination of heparin corrected for ideal body weight [12]. This was
then combined with the second compartment of a model described by Meesters and colleagues
[13] to yield the following equation:
Ct ¼ C0 � A� e











where A = 0.1, α = 10, and B = 0.9. The equation was imported into Microsoft Excel (Micro-
soft, Redmond, Washington, United States of America). Ideal body weight was calculated
using the Devine formula [16]. If total body weight was less than the ideal body weight, the for-
mer was used. The quantity of heparin in circulation at a given point in time (Ct) is calculated
based on the initial loading dose or the amount of heparin calculated to be present at the time
after the immediately previous administration (C0) and the time elapsed since the last adminis-
tration (t). At the conclusion of CPB, the final quantity of heparin within the system was calcu-
lated, and a protamine dose was administered at a ratio of 1-mg protamine for every 100 IU of
heparin remaining.
Laboratory and point-of-care investigations
Baseline investigations were performed following induction of anaesthesia, but prior to sys-
temic heparinisation. These were the following: kaolin ACT, kaolin and heparinase TEG,
full blood examination, prothrombin time (PT), and activated partial thromboplastin time
(aPTT). TEG parameters were measured using the TEG 5000 or TEG 6s devices (Haemonetics,
Braintree, Massachusetts, USA). These investigations were repeated 3 minutes after protamine
administration following separation from CPB to ensure complete circulation of protamine
before sampling was performed.
Primary and secondary outcomes
The primary outcome was kaolin TEG r-time at 3 minutes post-protamine administration.
This endpoint was chosen as it is far more sensitive to protamine-induced in vitro coagulation
abnormalities than ACT [17], is a commonly used point-of-care test in clinical practice, and
was the primary endpoint in the previous study we most closely sought to replicate [13]. Sec-
ondary outcomes were ratio of kaolin TEG r-time to heparinase TEG r-time at 3 minutes post-
protamine administration, ratio of kaolin TEG r-time pre-CPB to kaolin TEG r-time at 3 min-
utes post-protamine administration, ratio of kaolin ACT pre-CPB to kaolin ACT at 3 minutes
PLOS MEDICINE Optimal protamine dosing after CPB
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post-protamine administration mediastinal/pleural drainage 4 hours postoperatively, and
requirement for allogeneic red blood cell transfusion in the first 24 hours postoperatively.
Return to theatre for bleeding in the first 24 hours following the procedure was included as a
safety endpoint. Time points for postoperative measurement of mediastinal/pleural drainage,
transfusion requirement, and return to theatre were based on previous studies [18]. Observed
outcomes beyond these times were unlikely to be primarily related to heparin/protamine inter-
actions at the time of surgery.
Sample size calculation
The sample size was derived using summary measures of intrinsic rotational thromboelasto-
metry (INTEM) clotting time (CT) as a TEG r-time surrogate from a comparable population
[13]. Using a control post-protamine INTEM CT of 4.2 minutes, a standard deviation of
1.27 minutes, and a predicted effect size of 15%, simulations of the proposed design showed
that a total sample size of 212 participants would result in type I and II error rates of 3.6%
and 10%, respectively. The equivalent mean TEG r-time of the control group when trans-
formed from INTEM CT was predicted to be 8 minutes with a standard deviation of 2.5
minutes [19]. To allow for missing data caused by changes of surgical plan leading to exclu-
sion of a randomised participant, lack of follow-up data, or equipment malfunction, we
recruited 228 participants, with an initial randomisation ratio of 1:1 between intervention
and control groups.
Interim analysis
Interim analysis was planned after recruitment of 50% (n = 114) of the study cohort. At this
point, recruitment was paused, and data were considered. Specifically, the trial would be
stopped if the return to theatre rate was significantly increased in the intervention arms or
the t-statistic observed in the primary endpoint was higher than the prespecified futility
boundary (u1 = 1.8). If the primary outcome did not exceed the limits for safety or futility,
then the preplanned adaptation of the randomisation ratio was to be done according to
closed-form formulae in case of normality, while in the case of deviations from normality,
the randomisation ratio would be adapted to 1:1.33, in favour of the beneficial treatment
arm only if the observed treatment difference at the interim was half the predicted signifi-
cant difference (7.5%). If the difference was less than 7.5%, the randomisation ratio would
be maintained at 1:1 under deviations from normality. This is explained further in the Sup-
porting information appended to this manuscript (S2 Appendix). Deviations from normality
were determined through a significant (p< 0.05) Shapiro–Wilk test, and an observed differ-
ence exceeding the 7.5% threshold was observed. This triggered the randomisation rate that
ensured more patients received the treatment arm, while the study power of 90% was pre-
served under assumptions of an exponential distribution. To minimise bias, only the pri-
mary endpoint and safety variables were analysed. The interim and final analyses were
performed by 2 different statisticians. The clinical investigators remained blinded to any
change of randomisation strategy.
Statistical analysis
Primary efficacy analysis was carried out through a re-randomisation–based method, both
ensuring type I error was preserved despite deviations in assumptions (that could not be cor-
rected by transformation) and mitigating potential bias introduced by the adaptive design in a
single technique [20]. Participants were ordered by recruitment date, and their group assign-
ment was resampled at random 100,000 times using the design randomisation procedure and
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assuming no treatment difference (S2 Appendix). The p-value was determined by the propor-
tion of times that more extreme results than true results were observed by chance. Due to the
minor change in randomisation ratio, the treatment effect and associated 95% confidence
intervals were calculated using standard methods. For hypothesis testing, we report both stan-
dard p-values and a p-value that adjusts for the adaptive nature of the randomisation ratio as
explained above.
For secondary efficacy analyses, all continuous variables were summarised using
descriptive statistics depending on normality, specifically n (non-missing sample size),
mean, SD, median, and IQR. Frequency and percentages were reported for categorical mea-
sures. Data were reported using confidence intervals and p-values where appropriate. The
chi-squared test or Fisher exact test were used for categorical data and t tests or Mann–
Whitney U tests for continuous data. The full trial protocol is appended to this manuscript
(S1 Protocol). Trial enrolment, allocation, and follow-up were reported according to the
adaptive designs CONSORT extension statement (S1 Checklist) [21].
Results
Interim results
A mean reduction in r-time of 1.86 minutes between the intervention and control arms was
observed at interim analysis. The test statistic (−2.79) was below the predefined futility bound-
ary (u1 = 1.8). There was no significant difference in reoperation for bleeding (p = 0.34). Inves-
tigators were therefore allowed to recruit the second half of the study cohort. The Shapiro–
Wilk test for normality was performed as stipulated by the study protocol; we found that the
distribution of the primary outcome deviated significantly from normality (intervention,
p = 0.0061; control, p = 0.011), thus triggering our adaptive decision rules based on an expo-
nential distribution (S2 Appendix). As the relative difference between arms was 21.1% and
therefore greater than 7.5%, we adapted the randomisation ratio for the remaining participants
to be 1:1.33 as per the design.
Full study results
Participant characteristics. Participants were recruited between April 2018 and August
2019 with interim analysis in May 2019. Of 520 patients screened, 228 met study inclusion cri-
teria, consented to participate, and were randomised. Over the course of the study, 121 were
allocated to the intervention group and 107 to the control group. A total of 7 participants were
excluded from the intervention group due to inadvertent mechanical disruption during per-
formance of the baseline or repeat TEG (Fig 1), and 1 participant in the intervention group
was excluded due to lack of recorded data postoperatively. Participant characteristics, preoper-
ative laboratory studies, and pre-CPB TEG results were similar when compared (Table 1).
Heparin and protamine dosing. Pre-CPB heparin dosing was similar in both groups
(Table 2). A median reduction of 36.6% was observed in protamine dosing in the intervention
group relative to the control group (p< 0.001), translating to a lower initial protamine:heparin
ratio in the intervention group, based on the initial dose required to achieve a therapeutic
ACT for CPB (p< 0.001). A similar difference was noted when the same ratio was recalculated
for the total quantity of protamine administered relative to the initial dose of heparin when
accounting for any additional protamine administered (p< 0.001). No difference was noted in
the number of participants who required additional protamine within 4 hours postoperatively
(10 [8.3%] versus 9 [8.4%]; p = 1.00).
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Primary endpoint. The results from 221 participants were analysed for the primary end-
point (intervention group, n = 114; control group, n = 107). The mean TEG r-time measured 3
minutes post-protamine was significantly shorter in the intervention group, relative to the
control group (6.58 [SD 2.5] versus 8.08 [SD 4.0] minutes; p = 0.0016; standard p = 0.0011).
Fig 1. ACE flow diagram of trial progress. ACE, Adaptive designs CONSORT Extension; CONSORT, Consolidated Standards of Reporting Trials;
TEG, thromboelastography.
https://doi.org/10.1371/journal.pmed.1003658.g001
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The resultant standard treatment effect was a 1.5 (95% CI 0.61 to 2.39) minute reduction in
post-protamine TEG r-time in the intervention group relative to the control group.
Secondary endpoints. While the r-time in the intervention group was more closely
approximated to pre-CPB, a 25% increase in r-time post-CPB in the control group relative to
Table 1. Preoperative characteristics and covariates of participants allocated to the intervention (PRODOSE model) and control (fixed 1:1 ratio) groups.
Intervention (n = 121) Control (n = 107)
Female sex (n [%]) 30 (24.8%) 24 (22.4%)
Age, years 71.0 [61.0–77.0] 70.0 [63.5–75.5]
BMI (kg m−2) 28.2 [25.8–31.2] 28.6 [26.0–31.7]
BSA (m2) 1.92 (0.18) 1.98 (0.19)
Weight (kg) 81.75 (13.6) 85.6 (14.3)
EuroSCORE II 1.46 [0.85–2.18] 1.33 [0.84–2.23]
Preoperative aspirin (n [%]) 97 (80.2%) 85 (79.4%)
Hb concentration (g l−1) 137.5 (13.1) 137.1 (12.34)
Platelet count (× 109 l−1) 237 (69) 227 (63)
aPTT (s) 29.2 [28.1–31.4] 29.2 [27.5–31.0]
PT (s) 12.0 [11.3–12.6] 11.6 [11.0–12.1]
Creatinine (μmol/L) 80 [70–93] 79 [67–93]
Pre-CPB kaolin r-time (min) 6.07 (2.13) 5.69 (1.89)
Pre-CPB kaolin k-time (min) 1.39 (0.60) 1.39 (0.41)
Pre-CPB kaolin ɑ-angle (˚) 70.81 (5.95) 70.80 (5.82)
Pre-CPB kaolin MA (mm) 65.87 (5.62) 64.50 (4.68)
Operation type (n [%]) Ascending aorta 0 3 (2.8)
CABG 67 (55.4) 54 (50.5)
CABG + ascending aorta 1 (0.8) 0
CABG + valve 10 (8.3) 18 (16.8)
Valve 37 (30.6) 29 (27.1)
Valve + ascending aorta 6 (5.0) 3 (2.8)
Lowest temperature on CPB (˚C) 33.8 (1.46) 33.8 (1.66)
CPB time (min) 86 [71–106] 92 [71–118]
Values are number (proportion), mean (SD), and median [IQR].
aPTT, activated partial thromboplastin time; BMI, body mass index; BSA, body surface area; CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass; Hb,
haemoglobin; PT, prothrombin time.
https://doi.org/10.1371/journal.pmed.1003658.t001
Table 2. Unfractionated heparin and protamine dosing of participants allocated to the intervention (PRODOSE model) and control (fixed 1:1 ratio) groups.
Intervention (n = 121) Control (n = 107) p-value
Initial heparin dose (×103 IU) 27.0 [25.0–30.0] 28.0 [25.0–30.0] 0.098
Additional heparin required during CPB (n [%]) 56 (46.7) 56 (52.3) 0.47
Total heparin dose (×103 IU) 35.0 [30.0–40.0] 36.0 [32.0–41.0] 0.249
Initial protamine dose (mg) 180 [160–210] 280 [250–300] <0.001
Initial heparin:protamine ratio 0.66 [0.59–0.75] 1.0 [1.0–1.0] <0.01
Total protamine dose (mg) 210 [180–250] 310 [283–360] <0.001
Total heparin:protamine ratio 0.58 [0.53–0.65] 0.86 [0.79–1.0] <0.001
Values are number (proportion), mean (SD), and median [IQR].
CPB, cardiopulmonary bypass.
https://doi.org/10.1371/journal.pmed.1003658.t002
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baseline was noted (p< 0.001) (Table 3). No difference in the ratio of post-CPB heparinase
TEG to kaolin TEG ratio (p = 0.747) or in the ratio of ACT pre-CPB to post-CPB (p = 0.847)
was seen in the intervention group, relative to the control group. We detected no evidence of a
difference in mediastinal/pleural drainage at 4 hours postoperatively in the intervention group
relative to the control group (p = 0.85). Similarly, no evidence of difference was demonstrated
in requirement for allogeneic red blood cell transfusion in the first 24 hours postoperatively
(p = 0.69) or the number of units of PRBCs administered intraoperatively (p = 0.967) or post-
operatively (p = 0.719).
Additional data. Following administration of protamine, no clinically or statistically
significant differences were demonstrated in the intervention group relative to the control
group in mean haemoglobin concentration (100.7 [SD 13.7] g/L versus 101.7 [SD 11.7] g/L;
p = 0.559), median platelet count (145 [IQR 116 to 178] × 109/L versus 134 [112 to 166] × 109/
L; p = 0.153), median aPTT (39.5 [IQR 34.2 to 44.8] seconds versus 37.9 [IQR 32.8 to 42.1] sec-
onds p = 0.123), median PT (15.9 [IQR 14.7 to 16.8] seconds versus 16.0 [IQR 15.0 to 16.9] sec-
onds; p = 0.529), or median fibrinogen concentration (2.0 [IQR 1.7 to 2.4] g/L versus 2.1 [IQR
1.7 to 2.3] g/L; p = 0.559). No differences were noted in requirement for fresh frozen plasma or
prothrombin complex concentrate (19 [15.8%] versus 14 [13.1%]; p = 0.221), platelets (5
[4.2%] versus 2 [1.9%]; p = 0.451), or cryoprecipitate/fibrinogen concentrate (0 [0%] versus 3
[2.8%]; p = 0.103) up to 24 hours postoperatively.
Post-CPB TEG data are shown in Table 4 (in addition to the stated primary and secondary
outcomes). These were performed as post hoc exploratory analyses. The intervention group
was statistically superior in a variety of metrics, including kaolin k-time (p = 0.013), α-angle
(p = 0.002) and maximum amplitude (MA) (p = 0.05), and heparinase r-time (p = 0.003), k-
time (p = 0.01), and α-angle (p = 0.006).
Safety endpoint. No difference was noted in rate of reoperation for bleeding in the first
24 hours after the primary operation (3 [2.5%] versus 3 [2.8%]; p = 1.00).
Discussion
We conducted an adaptive, open-label, randomised superiority trial of mathematical model-
based protamine dosing versus a standardised 1:1 fixed ratio following CPB in patients pre-
senting for non-emergent cardiac surgery. We found that model-based dosing led to supe-
rior in vitro clot kinetics in the post-CPB period as measured by kaolin TEG r-time and that
Table 3. Secondary endpoints for participants allocated to the intervention (PRODOSE model) and control (fixed 1:1 ratio) groups.
Intervention (n = 121) Control (n = 107) p-value
Pre-CPB:post-CPB ACT ratio 0.98 [0.91–1.07] 0.99 [0.91–1.08] 0.847
Pre-CPB:post-CPB kaolin r-time ratio 0.96 [0.78–1.14] 0.75 [0.57–0.99] <0.001
Post-CPB heparinase r-time:post-CPB kaolin r-time ratio 1.02 [0.95–1.12] 1.02 [0.94–1.12] 0.747
Postoperative mediastinal/pleural drainage (mL) 140 [75–245] 135 [94–222] 0.849
Intraoperative PRBC requirement (n [%]) 11 (9.2%) 9 (8.4%) 1.0
Number of PRBC transfused intraoperatively (units) 2 [1–2] 2 [1–2] 0.967
Postoperative PRBC requirement (n [%]) 19 (15.8%) 14 (13.1%) 0.691
Number of PRBC transfused postoperatively (units) 1 [1–2] 1 [1–2.5] 0.719
Values are number (proportion) and median [IQR]. Postoperative mediastinal/pleural drainage was measured at 4 hours. Postoperative RBC requirement was measured
at 24 hours.
ACT, activated clotting time; CPB, cardiopulmonary bypass; PRBC, packed red blood cell.
https://doi.org/10.1371/journal.pmed.1003658.t003
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participants in the intervention group had a viscoelastic profile that more closely mirrored
their pre-CPB condition. Furthermore, we found that this result was achieved with a median
36.6% reduction in protamine dose. Despite this reduction in protamine dose, we found no
evidence of clinically or statistically significant difference in postoperative bleeding or trans-
fusion requirement.
Debate regarding the best numerical ratio has been ongoing for some time [22,23] and has
spurred the development of other techniques for optimised protamine dosing such as point-
of-care, individualised titration devices [24,25]. However, these are expensive, and their per-
formance is mixed [23–27]. Pharmacokinetic algorithms have been promoted as a cheaper,
more readily accessible alternative. Previous retrospective observational [13,28], prospective
observational [12,29–31], and pilot randomised controlled trials [32,33] have examined differ-
ent mathematical models for determining heparin concentration following CPB. Kjellberg and
colleagues have performed the sole, adequately powered randomised trial in the literature that
compares such a model to a fixed ratio approach [10]. Like our findings, this study demon-
strated a reduction in the amount of protamine required at the conclusion of CPB but did not
show a statistically significant difference in blood loss or transfusion.
It must be acknowledged that this trial was not designed or powered to detect a difference
in clinical endpoints, and type II error cannot be excluded. Our exclusion criteria were cho-
sen to minimise the risk of postoperative bleeding so that the effect of the intervention on
TEG r-time could be investigated without the potential confounding effects of major haem-
orrhage that is inherent to certain cardiac surgical procedures and patients. A similar trial
in a cardiac surgical population at higher risk for bleeding (i.e., complex aortic surgery and/
or preoperative heparin infusion), powered specifically to look at these outcomes, should be
considered.
There are a number of distinctions between our study and this previous work [10]. Notably,
Kjellberg and colleagues did not quantitatively measure any coagulation function (other than
ACT) as an endpoint, limiting their analysis to bleeding and transfusion. We chose viscoelastic
testing as our primary outcome measure for 3 reasons: Firstly, TEG and similar devices are
able to detect in vitro abnormalities at far lower protamine concentrations than ACT [17],
and, in some prospective studies, are more predictive of postoperative bleeding than conven-
tional coagulation tests [34]. We acknowledge that the relationship between deranged visco-
elastic metrics and bleeding is inconsistent when multivariate analysis is performed [35].
Secondly, following the publication of Karkouti and colleagues [36], viscoelastic testing now
forms the basis of many integrated transfusion algorithms in cardiac surgery, and, therefore,
Table 4. Kaolin and heparinase post-CPB TEG results for participants allocated to the intervention (PRODOSE
model) and control (fixed 1:1 ratio) groups.
Intervention (n = 121) Control (n = 107) p-value
Post-CPB kaolin k-time (min) 1.56 (0.52) 1.93 (1.49) 0.013
Post-CPB kaolin ɑ-angle (˚) 69.23 (5.66) 66.14 (8.45) 0.002
Post-CPB kaolin MA (mm) 61.70 (6.16) 60.07 (6.12) 0.05
Post-CPB heparinase r-time (min) 6.63 (3.00) 7.99 (3.72) 0.003
Post-CPB heparinase k-time (min) 1.53 (0.62) 1.80 (0.94) 0.01
Post-CPB heparinase ɑ-angle (˚) 69.08 (7.40) 66.03 (8.92) 0.006
Post-CPB heparinase MA (mm) 59.60 (6.08) 58.75 (6.75) 0.325
Values are mean (SD).
CPB, cardiopulmonary bypass; MA, maximum amplitude; TEG, thromboelastography.
https://doi.org/10.1371/journal.pmed.1003658.t004
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the incorporation of TEG into our study, combined with easily measured and clinically rele-
vant secondary outcomes, make our results more generalisable (within the limits of the study
design and exclusion criteria). Finally, TEG r-time was the primary outcome in the studies
whose findings we most closely sought to confirm [4,13]. Another point of differentiation with
Kjellberg and colleagues is our use of an adaptive design. This adaptive randomisation is a sig-
nificant advantage—as well as a check for futility and safety; the interim analysis allowed adap-
tation of the randomisation ratio to recruit a higher number of patients to the arm trending
towards benefit while preserving study power.
We acknowledge some limitations. Firstly, the surgeon and anaesthetist were not blinded
to the group allocation. Any potential bias related to this was minimised by standardisation
of coagulation management in the pre-CPB period, in the immediate post-CPB period, and
in the first 24 hours postoperatively, and by the selection of quantitative rather than qualita-
tive endpoints. Secondly, our model does not correct for the effects of possible hypothermia
during CPB. Hypothermic CPB decreases heparin requirements [37], likely as a conse-
quence of reduced heparin metabolism at lower temperatures [38]. This problem will not be
resolved until the rate of heparin metabolism at differing temperatures is better defined and
will require a continuous temperature input into any associated model. Thirdly, we did not
measure intraoperative blood loss, as this is challenging to do accurately during cardiac sur-
gery [39]. Kjellberg and colleagues did attempt to measure intraoperative blood loss and
detected no statistically significant median difference (300 [IQR 200 to 500] versus 400
[IQR 250 to 500] mL; p = 0.219). Fourthly, our study made use of 2 types of TEG device
depending on the recruiting centre (TEG 5000 or TEG 6s). The concordance between these
devices appears consistent in the cardiac surgical setting [40]. Additionally, the study exclu-
sion criteria mean the results cannot be generalised to certain groups (notably, obese
patients, children, and those with end-stage kidney disease requiring dialysis). These
patients should be the subject of further prospective validation. Finally, we did not make a
further, formal assessment of coagulation beyond the 3-minute mark following protamine
administration. Protamine is recognised as having a short biological half-life, with elimina-
tion from the circulation within 5 minutes [41]. Ergo, we cannot be certain that the observed
effect on TEG r-time would have persisted beyond this initial measurement. However, the
anticoagulant and antiplatelet effects of protamine are known to persist beyond this time
[42], and increased protamine-to-heparin ratio has been linearly associated with prolonged
postoperative bleeding [9].
We conclude that the PRODOSE model delivers improved in vitro metrics of clot firmness
(specifically, our primary endpoint, TEG r-time) when compared to a fixed 1:1 ratio based on
the initial dose of heparin required to achieve a therapeutic ACT for CPB. The model reduces
the dose of protamine required by a median of 36.6%. In this population, this approach
appeared safe. Further studies are necessary to determine whether there is a clinical benefit to
this approach in patients undergoing cardiac surgery at higher risk for bleeding.
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